Astellas Pharma

Astellas Pharma FCF Yield

The Free Cash Flow Yield of Astellas Pharma (4503.T) as of Nov 5, 2026 is 11.54 %. In the previous year, Free Cash Flow Yield was 3.74 % — a change of 208.93% (higher).

FCF Yield

11.54 %

YoY

208.93%

Last updated:

Free Cash Flow Yield of Astellas Pharma is 2026 11.54 % . Free Cash Flow Yield of Astellas Pharma was 2025 3.74 % . It decreases by 208.93% higher compared to the previous year.

The Astellas Pharma FCF Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Yield
Date
FCF Yield
Jan 1, 2019
5.36 JPY
Jan 1, 2020
3.27 JPY
Jan 1, 2021
5.21 JPY
Jan 1, 2022
4.11 JPY
Jan 1, 2023
5.43 JPY
Jan 1, 2024
3.25 JPY
Jan 1, 2025
3.74 JPY
Jan 1, 2026
11.54 JPY
The Astellas Pharma FCF Yield history
YEARFCF YieldYoY
11.54 %+208.93%
3.74 %+14.90%
3.25 %-40.11%
5.43 %+32.17%
4.11 %-21.10%
5.21 %+59.19%
3.27 %-39.00%
5.36 %-18.37%
6.57 %+38.98%
4.73 %-26.43%
6.42 %+70.68%
3.76 %-11.95%
4.27 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Astellas Pharma Stock analysis

What does Astellas Pharma do? Astellas Pharma Inc. is a global pharmaceutical company based in Tokyo, Japan. The company manufactures and distributes medications worldwide. It was formed in April 2005 through the merger of two well-known Japanese pharmaceutical companies - Yamanouchi and Fujisawa. This merger created one of Japan's largest pharmaceutical companies and allowed for collaboration on the global market and the development of new innovations in medication research. Astellas' business model is focused on targeted research and development, comprehensive marketing and distribution networks, and collaboration with international partners. The company's main areas of focus are cancer, urology, transplantation, anti-infectives, and pneumology. Astellas has expanded its business through acquisitions and partnerships and currently operates in over 50 countries worldwide. In addition to pharmaceutical production, the company also provides services and consulting in the medical and health sectors. Astellas' business is divided into segments including pharmaceuticals, medical devices, and diagnostics. The pharmaceutical segment is the largest and offers a wide range of prescription medications for various medical areas. The medical devices segment specializes in the development and manufacturing of medical devices such as catheters, stents, and heart valves. The diagnostics segment focuses on developing and producing testing systems and instruments for diseases such as HIV and infectious diseases. Overall, Astellas is an important player in the global pharmaceutical and health industry, known for its innovative research, wide range of products, and collaboration with partners to develop campaigns against various diseases. Astellas Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Astellas Pharma stock

Free Cash Flow Yield of Astellas Pharma is 11.54 % in 2026.

Free Cash Flow Yield of Astellas Pharma changed from 3.74 % to 11.54 %, representing a 208.93% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield Astellas Pharma since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's Astellas Pharma with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Astellas Pharma

All Key Metrics — Astellas Pharma